Abstract
The landscape of cancer research is swiftly evolving, presenting fresh optimism through innovative tactics that customize treatment for each patient. In 2016, Clevers unveiled a groundbreaking study in Cell, introducing organoids that emulate essential structural and functional traits of organs like the kidney, lung, gut, brain, and retina. This technology enables the replication of human organ development and various pathologies within a controlled laboratory environment. Mounting evidence underscores the potential of patient-derived organoids (PDOs) to reshape cancer treatment and revolutionize drug discovery in oncology. This commentary explores these pioneering research avenues and their profound implications for clinical oncology and pharmaceutical development.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
